Thus, the lack of functional validation of the H1153Y-KCNH2 mutation has long remained a missing key proof for a relevant clinical exploitation and previously associated LQTS must be interpreted with caution [12]. This evidence concerns the gene KCNH2 and familial long QT syndrome.